Insulin-like growth factor binding proteins related to progression-free survival (PFS) and overall survival (OS) in advanced non-small cell lung cancer (NSCLC) patients treated with chemotherapy.

Targeting the insulin-like growth factor receptor pathway in lung cancer: problems and pitfalls

“…Levels of serum IGFBPs appear to be prognostic in NSCLC patients whether they are treated with an epidermal growth factor receptor (EGFR) tyrosine kinase receptor (TKI) drug or systemic chemotherapy [Fidler et al . 2009; Karmali et al . 2010].…”

“…IGFBP-3, in particular, displays antiproliferative effects and pro-apoptotic effects both through and independently of the p53 downstream pathway [Buckbinder et al 1995;Butt et al 2000;Devi et al 2000;Santer et al 2006;Kim et al 2004]. Levels of serum IGFBPs appear to be prognostic in NSCLC patients whether they are treated with an epidermal growth factor receptor (EGFR) tyrosine kinase receptor (TKI) drug or systemic chemotherapy [Fidler et al 2009;Karmali et al 2010]. Similar prognostic significance of IGFBPs was also recently recorded for early stage, surgically resected NSCLC [Shersher et al 2011].…”

Serum Biomarkers May Prognosticate Recurrence in Node-Negative, Non-Small Cell Lung Cancers Less Than 4 Centimeters

“…All serum samples were assayed simultaneously by a blinded technician for serum biomarkers hypothesized to have value for risk stratifying patients for early recurrence. These biomarkers were chosen based on our previous work and sampled biological processes associated with metastatic progression, including angiogenesis, energy metabolism, apoptosis, and inflammation [11][12][13][14][15][16][17][18][19][20][21]. Pretreatment serum specimens were prepared using standard techniques, supplemented with 25 mL/mL mammalian protease inhibitor cocktail (Sigma-Aldrich, St. Louis, MO), and archived at À80 C in aliquots with no specimen subjected to more than two freeze-thaw cycles, as previously described [12,18].…”

“…The biomarkers chosen for investigation in the current study were based on our previous work aimed at the development of blood-based multiple analyte panels to help guide clinical decision making [11][12][13][14][15][16][17][18][19][20][21]. They sample biological processes associated with metastatic progression, including angiogenesis, energy metabolism, apoptosis, and inflammation.…”